StockData

Spyre Therapeutics, Inc. (SYRE) stock

SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$93.81−5.56 (-5.60%)

Close on Nov 17, 2026Market cap $8.27BP/E –Yield –

Spyre Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Spyre Therapeutics's enterprise value was $8.31B on Nov 11, 2026, against $1.33B a year earlier. Over the last 5 years it ranged from -$197.64M to $8.31B, with a median of $376.16M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$8.31B+455.7%
2025Dec 31, 2025$1.49B+91.1%
2024Dec 31, 2024$782.26M–
2023Dec 29, 2023-$116.47M–
2022Dec 30, 2022-$47.53M-139.0%
2021Dec 31, 2021$121.78M-42.5%
2020Dec 31, 2020$211.75M+60.1%
2019Dec 31, 2019$132.27M+31.2%
2018Dec 31, 2018$100.82M+201.7%
2017Dec 29, 2017$33.42M–
2016Dec 30, 2016-$9.58M–

More Spyre Therapeutics figures

See a number that looks wrong?